Compass Therapeutics Inc (CMPX) 뉴스

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update

Received FDA Fast Track Designation for the investigation of CTX-009 in combination with paclitaxel for the...

Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated

CTX-009, the Company’s bispecific DLL4/VEGF-A antibody, in combination with paclitaxel, has shown promising...

Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors

The first patient was dosed in the Phase 1 dose escalation trial of CTX-8371.This study is conducted in...

Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference

BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage...

Compass Therapeutics to Participate in the Stifel Targeted Oncology Days

BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage...

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Major Histocompatibility Complex Class I (MHC-I) negative tumors are refractory to immune-oncology therapies...

Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update

Enrollment in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in...

Form 4 - Statement of changes in beneficial ownership of securities

Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage...

Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial

CTX-8371, a bispecific checkpoint inhibitor that simultaneously targets PD-1 and PD-L1, exhibits a novel...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities